Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 11 to 20 of 334

TitleReference numberPublishedLast updated
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancerTA1136
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1129
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancerTA1130
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancerTA1127
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122
Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiencyTA1117
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Low-energy contact X-ray brachytherapy for rectal cancerHTG763
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109

Results per page

  1. 10
  2. 25
  3. 50
  4. All